Overall, based on the complete absence of homing of cells in lungs of osimertinib pre-treated mice, in both weekly and daily regimens, EGFR-TKI pretreatment may represent a viable treatment option in delaying the onset of disease in patients as an adjuvant treatment post resection of early-stage tumors or among patients with pre-disposition to EGFR mutant lung cancers harboring germline EGFR kinase domain mutations [17,18]. This evidence concerns the gene EGFR and lung carcinoma.